Chimeric Antigen Receptor-Engineered T Cell Therapy in Acute Myeloid Leukaemia

Acute myeloid leukaemia (AML) is a disease with a very poor outcome and remains an area of significant unmet need, necessitating novel therapeutic strategies. The progress made in the field of immunotherapy, in particular chimeric antigen receptor (CAR)-engineered T cells, has given rise to many hop...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Etienne Paubelle, Clément Rocher, Edith Julia, Xavier Thomas
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	European Medical Journal 2018-09-01
Edice:	European Medical Journal
Témata:	acute myeloid leukaemia (aml) chimeric antigen receptor (car) t cells immunotherapy
On-line přístup:	https://www.emjreviews.com/hematology/article/editors-pick-chimeric-antigen-receptor-engineered-t-cell-therapy-in-acute-myeloid-leukaemia/
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!